Bluejay Diagnostics Q4 2024 Earnings Report

Bluejay Diagnostics EPS Results

• Actual EPS: -$449.48
• Consensus EPS: -$144.00
• Beat/Miss: Missed by -$305.48
• One Year Ago EPS: N/A

Bluejay Diagnostics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bluejay Diagnostics Announcement Details

• Quarter: Q4 2024
• Date: 3/31/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Bluejay Diagnostics (NASDAQ:BJDX) (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments.

Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.